The GLP is committed to full transparency. Download and review our 2019 Annual Report

Chemical companies: Reform WHO’s ‘rogue’ IARC cancer-designating agency

| | January 31, 2017
Screen Shot at AM
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Launching what it called a campaign for accuracy in public health research, the American Chemistry Council, which represents U.S. chemical companies, said the International Agency for Research on Cancer’s (IARC) evaluations “have a significant impact on U.S. public policy” and should be based on “transparent, thorough assessment of the best available science”.

As part of its work on cancer research, IARC publishes evaluations – known as monographs – on whether certain chemicals, lifestyles and activities may cause cancer … IARC has repeatedly defended its work as scientifically sound and says its monographs are “widely respected for their scientific rigor, standardized and transparent process and … freedom from conflicts of interest”.

The WHO agency is also embroiled in a row with Congress, the U.S. National Institutes of Health and the European Food Safety Authority over its review of the weedkiller glyphosate.

IARC classifies glyphosate, a key ingredient of Monsanto Co’s herbicide Roundup, as “probably carcinogenic”, but that assessment is at odds with many government regulators, including those in the United States, Europe, Canada, Japan and New Zealand, who say it is unlikely to pose a cancer risk to humans.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: U.S. chemical industry body calls for reform of WHO cancer agency

Related article:  Careless farming could cost us benefits of GM crops
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend